Keay Nake

In a report published Wednesday, Ascendiant Capital analyst Keay Nakae reiterated a Buy rating on Biolase (NASDAQ: BIOL), but lowered the price target from $6.50 to $5.50. In the report, Ascendiant Capital noted, “We continue to believe that Biolase is well positioned in the dental laser market....

In a report published on Tuesday, Ascendiant analyst Keay Nakae initiated coverage on Synthetic Biologics (NYSE: SYN) with a Buy rating and $2.25 price target. In the report Ascendiant commented, "The Company has an exclusive channel collaboration with privately held Intrexon Corporation, which...